Document Detail


The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.
MedLine Citation:
PMID:  22022769     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This review provides a systematic overview of the influence of the third generation beta-adrenoceptor antagonists on vascular and/or endothelial function at a cellular level as well as of the advantages of their application in hypertension, heart failure and coronary artery disease. Drugs antagonizing the beta-adrenoceptors have been in use for the treatment of hypertension for decades. In systolic heart failure and post-myocardial infarction, beta-adrenoceptor antagonists were proven to be effective in decreasing the number of deaths and improving morbidity. However, betaadrenoceptor antagonists are a heterogeneous drug group, consisting of agents with different selectivity for adrenoceptors and/or additional effects in heart and peripheral circulation. Beta-adrenoceptor antagonists comprise a multitude of different agents, which may have additional properties exceeding the pure receptor blockade. These features may provide additional benefit in the treatment of hypertension. The third generation drug nebivolol exerts a nitric oxide-mediated vasodilating activity which has positive effects on intima and media thickness and arterial rigidity, a major risk factor in cardiovascular disease. Moreover, anti-proliferative, anti-inflammatory, and anti-oxidative properties have been detected for carvedilol and nebivolol, contributing to their additional value in treatment of hypertension and heart failure.
Authors:
Markus Wehland; Jirka Grosse; Ulf Simonsen; Manfred Infanger; Johann Bauer; Daniela Grimm
Related Documents :
18158469 - Inotropes in the management of acute heart failure.
9146689 - Congestive heart failure in elderly patients.
16230259 - The irbesartan in heart failure with preserved systolic function (i-preserve) trial: ra...
20559969 - Endoventricular electromechanical mapping-the diagnostic and therapeutic utility of the...
9894619 - Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery dis...
7670289 - Acute congestive heart failure: pathophysiological alterations.
19327519 - Surgical management of multiple ventricular septal defects: the role of the felt sandwi...
1773569 - Case report: isolated right coronary artery obstruction presenting as acute anterior my...
7834729 - Catheter sizes for quantitative coronary arteriography.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  10     ISSN:  1875-6212     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-02     Completed Date:  2012-07-27     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  378-90     Citation Subset:  IM    
Affiliation:
Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke University, Magdeburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology*,  therapeutic use
Animals
Benzopyrans / pharmacology,  therapeutic use
Carbazoles / pharmacology,  therapeutic use
Cardiovascular Diseases / drug therapy*,  physiopathology
Ethanolamines / pharmacology,  therapeutic use
Heart Failure / drug therapy,  physiopathology
Humans
Hypertension / drug therapy,  physiopathology
Nitric Oxide / metabolism
Propanolamines / pharmacology,  therapeutic use
Risk Factors
Vasodilation / drug effects*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Benzopyrans; 0/Carbazoles; 0/Ethanolamines; 0/Propanolamines; 030Y90569U/nebivolol; 0K47UL67F2/carvedilol; 10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis...
Next Document:  Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome: Role of the Mineralocorticoid Re...